Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age

17Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Betuela, I., Bassat, Q., Kiniboro, B., Robinson, L. J., Rosanas-Urgell, A., Stanisic, D., … Mueller, I. (2012). Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrobial Agents and Chemotherapy, 56(4), 2146–2149. https://doi.org/10.1128/AAC.05566-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free